Issue Special Issue 1/2008
Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection
Content (368 Articles)
Clinical effect of interleukin-2 (IL-2) immuno-adjuvant treatment in HIV+ advanced naïve patients
C Tincati, M Cesari, L Meroni, F Bai, GM Bellistrì, M Galli, ME Moroni, A d'Arminio Monforte, GM Marchetti
Pathogenesis of HIV infection: implications for treatment and prevention
HC Lane
O112 Trends in transmitted HIV drug resistance among non-B subtypes in the UK
D Chilton, L Harrison, H Green, S Lattimore, V Delpech, D Pillay
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
JM Molina, C Cordes, P Ive, A Vibhagool, S Vanveggel, P Williams, K Boven
Impact of antiretroviral dosing and daily pill burden on viral rebound rates in naive patients receiving a tenofovir-based regimen
A Ammassari, P Lorenzini, F Maggiolo, G Sterrantino, A Corpolongo, G Rizzardini, N Abrescia, A Chirianni, M Foggia, C Mussini, N Gianotti, M Andreoni, CF Perno, A Antinori
O113 HIV-1 clade C resistance genotypes after first virological failure in a large community ART programme
C Orrell, RP Walensky, E Losina, KA Freedberg, R Wood
The implications beyond public health if we don't manage the HIV epidemic
A Whiteside
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz in antiretroviral-naïve patients through 7 years
JVR Madruga, I Cassetti, A Etzel, JMA Suleiman, Y Zhou, AK Cheng, J Enejosa
O114 NNRTI mutations are efficiently transmitted within clusters of new HIV infections
BG Brenner, T d'Aquin Toni, M Roger, JP Routy, D Moisi, MA Wainberg
Effects of NRTI backbone on HIV RNA, CD4 counts and lipids for first-line boosted PI-based HAART: meta-analysis of 12 clinical trials in 4,896 patients
AM Hill, WA Sawyer
O115 Importance of detecting minority variants in the clinical management of HIV
D Kuritzkes
A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adults
TW Mahungu, LJ Else, CJ Smith, Z Cuthbertson, D Podlekareva, P Hay, UB Dragsted, SH Khoo, MA Johnson, DJ Back, M Youle
Similar virological response rates for ART-naïve subjects starting KVX + LPV/r or TVD+ LPV/r. Data from the prospective observational STAR cohort
E Wolf, A Trein, W Schmidt, A Baumgarten, H Jaeger, HJ Stellbrink
O122 Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, Kenya
GK Kigen, S Kimaiyo, DJ Back, SE Gibbons, E Sang, IG Edwards, A Owen, SH Khoo
Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE study
J Uy, R Yang, A Thiry, J Absalon, A Farajallah, JF Maa, D McGrath
O123 To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV Paediatric Study (CHIPS)
AS Walker, KL Boyd, K Doerholt, H Lyall, E Menson, K Butler, P Tookey, A Riordan, D Shingadia, A Judd, G Tudor-Williams, DM Gibb
Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz
RJ Bedimo, H Drechsler, M Holodniy, M Pasley, W Woodward
O124 Efavirenz and rifampicin in the South African context: is there a need to dose increase efavirenz with concurrent rifampicin therapy?
C Orrell, K Cohen, P Ive, I Sanne, R Wood
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppression
L Malincarne, A Sgrelli, G Camanni, R Papili, D Francisci, F Baldelli
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
C Kityo, AS Walker, F Lutwana, F Ssali, R Nalumenya, D Tumukunde, J Kawiya, P Munderi, A Reid, CF Gilks, DM Gibb, SH Khoo
Evaluating affordable screening markers to detect HIV-1-infected Ugandan adults with CD4 counts of less than 200 cells/mul
GM Miiro, J Todd, S Nakubulwa, C Watera, P Hughes, P Munderi, S Floyd, H Grosskurth
Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice – 2-year data from the German Outpatient Cohort
J van Lunzen, G Fätkenheuer, T Lutz, S Klauke, S Mauss, H Knechten, P Braun, L Gallo, B Ranneberg
O131 Where are we with National and International guidelines?
E Katabira
The Rainbow Cohort: saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients – 48-week results from Germany
H Knechten, C Stephan, T Lutz, A Stoehr, A Carganico, G Knecht, K Schewe, H Jaeger, C Mayr, FA Mosthaf, E Wolf, E Wellmann, A Tappe
O135 Seek and treat for optimal prevention of HIV/AIDS (STOP HIV/AIDS)
JSG Montaner
Comparing the efficacy of Truvada® and Kivexa® combination therapy in HAART-naive individuals with different viral loads
RH Daniels, BG Gazzard, P Holmes, A Scourfield, M Bower, M Nelson
The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients
S Das, J Arumainayagam, B Kumari, S Chandramani, L Riddell, M Ghanem
O134 HIV disease management and challenges in Eastern Europe and Central Asia
A Bobrik
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
B Graf, K Taylor, A Gupta, BG Gazzard, M Nelson
O211 HIV and the brain: neuro-inflammation long-term, CNS control of HIV replication, brain disease in suppressed patients and differential penetration of drugs
D Clifford
HAART in HIV+ naive elderly patients: immuno-virological response and clinical outcome
BM Celesia, F Bisicchia, R La Rosa, S Mavilla, M Gussio, MT Mughini, F Palermo, R Russo
O212 Rate of change in CD4 counts in patients with stable HIV viremia
AN Phillips, B Ledergerber, JR Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren, A Mocroft
Nevirapine (NVP), tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) is effective and well tolerated in naïve HIV-1 infected patients
M Bickel, P Gute, A Carlebach, A Mueller, S Klauke
O213 CD4-guided STI in patients responding to HAART
F Maggiolo, M Airoldi, A Callegaro, C Martinelli, A Dolara, T Bini, G Gregis, P Quinzan, V Ravasio, F Suter
Comparison of the efficacy at 48 weeks of first-line antiretroviral treatment for HIV infection in 1998 and 2006: a multicentric investigation
F Sozio, V Soddu, G De Socio, M D'Alessandro, E Polilli, G Madeddu, P Bonfanti, E Mazzotta, J Vecchiet, MS Mura, T Quirino, L Manzoli, G Parruti
O214 The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy
C Cohen, A Colson, G Pierone, E DeJesus, F Kinder, R Elion, D Skiest, A Habel, J Jensen, J Garb, H Schrager
Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profile
F Blanco, M Arredondo, F Guevara, C Garrido, J Morello, S Rodríguez-Nóvoa, M Córdoba, J González-Lahoz, V Soriano
O221 Optimising paediatric treatment for long term survival. Adult survivors of congenital HIV infection – what problems will they have?
H Lyall
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
C Katlama, N Bellos, B Grinsztejn, A Lazzarin, A Pozniak, S De Meyer, T Van De Casteele, S Spinosa-Guzman
O222 Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial
DM Gibb, A Compagnucci, H Green, M Lallemant, Y Saidi, N Ngo-Giang-Huong, C Taylor, L Mofenson, F Monpoux, MIG Tomé, M Marczyñska, D Nadal, U Wintergerst, S Kanjavanit, H Lyall, C Giaquinto, J Moye
Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients
D Bánhegyi, C Katlama, C Da Cunha, S Schneider, A Rachlis, O Romanenko, C Workman, A Vandevoorde, F Tomaka, T Vangeneugden, S Spinosa-Guzman
O223 Antiretroviral Pregnancy Registry (APR) at 10,000 prospective reports
KP Beckerman, D Covington, K Dominguez, A Scheuerle, VX Vannappagari, DH Watts, H Tilson
Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials
N Clumeck, B Clotet, MA Johnson, M Peeters, J Vingerhoets, G Beets, G De Smedt
O224 The early AIDS epidemic in the U.S.: views from Atlanta and Hollywood
H Jaffe
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
A Pozniak, K Arastéh, JM Molina, B Grinsztejn, S De Meyer, T Van De Casteele, S Spinosa-Guzman
O231 Cryptogenetic liver disease, steatosis, portal hypertension, transaminitis and antiretrovirals
S Pol
Antiretroviral tolerability and efficacy after switch to saquinavir in PI-experienced patients: 48-week analysis of the German Rainbow Cohort
C Stephan, H Jaeger, A Carganico, G Knecht, T Lutz, C Mayr, FA Mosthaf, S Koeppe, M Mueller, E Wolf, A Tappe, E Wellmann, H Knechten
Tipranavir in highly ARV-experienced patients: efficacy and tolerability results from the French prospective NADIS cohort
C Allavena, P Flandre, P Pugliese, MA Valantin, J Izopet, R Garraffo, I Poizot, A Cabie, Y Yazdanpanah, L Cuzin, C Duvivier, C Katlama, P Dellamonica
O233 Surrogate markers for liver damage (i.e. how can we measure the extent of fibrosis and disease without biopsy)
M Puoti
Reduction in AIDS defining events/deaths with etravirine (ETR; TMC125) compared to placebo: pooled DUET 48-week results
R Haubrich, J Eron, M Thompson, P Reiss, R Weber, M Peeters, R Van Solingen-Ristea, G Beets, E Voorspoels, G De Smedt
O311 Pathogenesis of non-AIDS morbidities in HIV disease and implications for management
S Deeks
Patient retention on antiretroviral therapy programme: risk factor analysis of a Uganda cohort
EJ Mills, P Olupot-Olupot, C Cooper, J Meadway, H Boorman, A Das, JSO Obbo
O312 Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors
JD Lundgren
INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patients
J Reynes, I Pellegrin, G Peytavin, M Wirden, B Giffo, C Aquilina, A Pinta, N Pierre, S Kraemer, V Calvez
O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH) – myocardial infarction and abacavir use
JD Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss, JD Lundgren
CD4+ guided antiretroviral treatment interruption. A meta-analysis
A De Silvestri, A Boschi, C Tinelli, E Seminari
O314 Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:D study group
K Petoumenos, E Fontas, SW Worm, R Weber, S De Wit, M Bruyand, CA Sabin, P Reiss, W El-Sadr, A d'Arminio Monforte, N Friis-Møller, JD Lundgren, MG Law
Raltegravir therapy in HIV multi-experience patients: safety and efficacy
P Meraviglia, A Capetti, S Merli, F Mazza, V Micheli, G Rizzardini
O321 Management of renal disease in HIV infection for the HIV physician
I Williams
Virological and immunological response to three boosted protease inhibitor regimens
C Baumgardt, C Stephan, AE Haberl, HR Brodt, M Stuermer, S Klauke, P Gute, M Bickel, P Khaykin, N von Hentig, S Staszewski
Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies
F Rodriguez-Arrondo, K Aguirrebengoa, J Portu, J Muñoz, MA Garcia, J Goikoetxea, E Martinez, JA Iribarren, N Perez, C Alcarez, B Clotet
O323 High HIV viral load inhibits osteoblast function and signalling
NS Chew, EJ Cotter, PP Doran, WG Powderly
Different metabolic and anthropometric characteristics of TVD, CBV or KVX associated with nevirapine: Results from the "NEVIRAPINE COMPANION" cohort
G Guaraldi, F Adorni, S Zona, N Squillace, G Orlando, C Stentarelli, R Esposito, C Sconiamilio
Antiretroviral treatment efficacy after mutations reversion during T20 monotherapy, an alternative strategy in multi-failed HIV-1 infected patients
S Lo Caputo, M Santoro, CSF Ceccherini-Silberstein, V Svicher, P Pierotti, F Vichi, R D'Arrigo, C Gori, CF Perno, F Mazzotta
O331 Patterns of viral suppression on cART as predictors of uncontrolled viremia after starting a new antiretroviral after 1 January 2003
J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, JD Lundgren
Antiretroviral treatment use and HIV-RNA suppression rates for 877 European patients in the etravirine expanded access programme
E Florence, S De Wit, A Castagna, E Ribera, AM Hill, R Ryan, H Vanaken, S Marks, Y van Delft
O332 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients
WP Bannister, A Mocroft, O Kirk, P Reiss, A d'Arminio Monforte, JM Gatell, M Fisher, H Trocha, A Rakhmanova, JD Lundgren
Switching from enfuvirtide to etravirine – efficacy results from the etravirine expanded access programme
E Ribera, E Florence, S De Wit, A Castagna, B Ryan, H Vanaken, AM Hill, S Marks
O333 Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART)
CJ Smith, FC Lampe, M Youle, MA Johnson, AN Phillips
Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir
A Canestri, C Blanc, M Wirden, G Peytavin, N Ktorza, C Katlama
O411 HIV-TB co-infection and TB drug resistance: an emerging threat to HIV and TB programmes
GH Friedland
Darunavir exhibits a potent activity as boosted PI in subjects on a salvage antiretroviral regimen
P Vitiello, S Ferramosca, M Lo Cicero, PDV Di Vincenzo, M Capasso, M Galli, ME Moroni, SR Rusconi
O412 Factors associated with poor clinical outcome among HIV-infected patients with tuberculosis (TB) in Europe and Argentina. The HIV/TB collaborative study
D Podlekareva, A Mocroft, FA Post, V Riekstina, JM Miro, H Furrer, M Bruyand, A Panteleev, E Girardi, JJ Toibaro, J Caylá, R Miller, N Obel, A Skrahin, E Malashenkov, JD Lundgren, O Kirk
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patients
A Imaz, S Villar del Saz, MA Rivas, A Curran, E Caballero, V Falco, M Crespo, I Ocana, M Diaz, E Ruiz de Gopegui, M Riera, E Ribera
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
J Lalezari, E DeJesus, O Osiyemi, P Ruane, Z Haigney, R Ryan, B Polsonetti, TN Kakuda, J Witek
Safety and efficacy of tipranavir co-administered with low-dose ritonavir in patients with advanced HIV-1 infection and limited treatment options
S Esser, A Moll, V Cairns, H Jaeger, S Mauss, J van Lunzen, J Goldbach
O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance
P Cahn, J Altclas, M Martins, M Losso, I Cassetti, S Cox, DA Cooper
Exposition and sequencing to antiretrovirals in HIV-1 patients with triple-class antiretroviral failure, and harbouring protease resistance mutations
JM Llibre, P Domingo, F Blanco, B Clotet, A Ocampo, JA García-Henarejos, P Geijo, C Rosa, J Hernandez-Quero, A Castro
O415 Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136
JF Delfraissy, S Moreno, J Sanz-Moreno, G Carosi, V Pokrovsky, A Lazzarin, G Pialoux, A Balogh, E Vandeloise, G Leleu
L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)
J Vachta, F Wiesmann, P Braun, R Ehret, C Höhn, A Tappe, H Knechten
O421 When to start therapy? The patient's viewpoint
G Cairns, K Alcorn
Positive predictive factors in HIV-1 patients treated with enfuvirtide plus an OB that include an active boosted PI. Preliminary FastFuz study results
E Ribera, A Antela, JA Garcia Henarejos, JR Arribas, JA Oteo, M Lopez Gomez, E Ferrer
O422 Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART?
LJ Waters, M Fisher, J Anderson, C Wood, CA Sabin
Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine
S Nozza, F Visco, A Soria, L Galli, S Salpietro, N Gianotti, E Carini, A Bigoloni, G Fusetti, G Tambussi, A Lazzarin, A Castagna
O423 Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive HAART: results from the German ClinSurv cohort
A Zoufaly, C Kreuzberg, M An der Heiden, C Kollan, O Hamouda, J van Lunzen
Efficacy and tolerance of combination of maraviroc with MK-0518, boosted TMC-114, TMC-125, in heavily pre-treated CCR5-positive patients
F Almasi, A Krivine, A Compangocci, B Silberman, L Belaebi, D Salmon
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
S De Meyer, E Lathouwers, I Dierynck, E De Paepe, B Van Baelen, T Vangeneugden, F Tomaka, MP de Béthune, G Picchio
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns
D Paraskevis, E Magiorkinis, G Magiorkinis, V Paparizos, MC Lazanas, M Chini, H Sambatakou, A Karafoulidou, A Hatzakis
O425 Efficacy and safety of maraviroc in treatment-experienced (TE) patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies
WD Hardy, R Gulick, HB Mayer, G Fätkenheuer, M Nelson, J Heera, N Rajicic, J Goodrich
Darunavir in patients who failed on fos-amprenavir: efficacy at week 48
S De Wit, M Delforge, K Kabeya, C Necsoi, N Clumeck
Etravirine use in clinical practice: 48-week data from a single centre cohort
C Scott, N Khatib, M Bower, BG Gazzard, M Nelson
Transient therapy with quadruple NRTI provides immune stability in patients with multidrug resistant HIV-1 and no options for suppressive regimens
A Bonjoch, JM Llibre, E Negredo, J Puig, N Pérez-Álvarez, MJ Buzon, J Martinez-Picado, B Clotet
Efficacy, safety and tolerability of enfuvirtide in a population of Portuguese HIV-1 chronically infected patients
AC Miranda, I Almeida, J Mendez, M Mota, E Teofilo, J Vera, A Diniz, F Maltez, R Marques, K Mansinho, R Sarmento-Castro, R Camacho, MJ Manata, C Delgado
Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated HIV patients (pts)
F Gatti, A Matti, P Nasta, G Cologni, S Costarelli, G Carosi
Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results
J Mallolas, D Podzamczer, P Domingo, P Echeverría, E Ribera, F Gutierrez, H Knobel, J Cosín, E Ferrer, JA Arranz, V Roca, J Pich, E de Lazzari, JM Gatell
48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial
E Ribera, B Clotet, E Martínez, V Estrada, J Sanz, J Berenguer, R Rubio, F Pulido, M Larrouse, A Curran, E Negredo, P Ferrer, ML Álvarez
FREE trial: induction therapy with ART (abacavir/lamivudine/lopinavir/r) followed by maintenance regimen with triple NRTI, compared to continued ART
HG Sprenger, CHH ten Napel, R Vriesendorp, IM Hoepelman, JC Legrand, PP Koopmans, ME Kasteren, B Bravenboer, RW ten Kate, PHP Groeneveld, TS van der Werf, EH Gisolf, C Richter
Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing
M Brandolini, A Cattelan, A Orani, L Sighinolfi, M Andreoni, G Nardini, G Sotgiu, R Maserati
Substitution of nevirapine for efavirenz in virologically controlled patients intolerant of efavirenz
DJ Ward, JM Curtin, EJ Miller
Efficacy and safety of switching enfuvirtide to raltegravir in patients with viral suppression
JR Santos, JM Llibre, J Moltó, N Perez, MC García, B Clotet
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients
M Bickel, A Bodtlaender, G Knecht, M Kurowski, S Klauke, T Lutz
Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DF
RF Viergever, MJ ten Berg, WW van Solinge, AIM Hoepelman, EH Gisolf
Simplification of therapy (ART) with efavirenz/emtricitabine/tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patients
B Young, E DeJesus, JO Morales-Ramirez, R Ebrahimi, JF Maa, D McColl, A Farajallah, D Seekins, JF Flaherty
Does HIV-1 tropism change in patients during virological suppressive therapy?
O Degen, C Noah, K Colberg, S Hertling, J van Lunzen
Patient-reported outcomes after simplification to a single tablet regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF)
S Hodder, K Mounzer, E DeJesus, JF Maa, R Ebrahimi, K Grimm, JF Flaherty, A Farajallah
Induction strategy with enfuvirtide: results from the Fuziona study, a multicenter retrospective study in Spain
M Mora, C Navarro, A Gonzalez-Mena, J Rodriguez-Baños, B Clotet, JL Blanco, JR Blanco, JC Lopez-Bernaldo de Quiros, J Hernandez-Quero, P Arazo, J Flores, JR Arribas
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
P Echeverría, J De la Torre, J Pasquau, E Casas, T Puig, E Ribera, I Bravo, R López, B Clotet, E Negredo
Simplification from TPV/RTV 500/200 BID to TPV/RTV 500/100 BID guided by therapeutic drug monitoring
J Morello, S Rodríguez-Nóvoa, F Blanco, I Jiménez-Nácher, G González-Pardo, AJ Rubio, V Soriano
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy
P Echeverría, P Domingo, M Gutierrez, G Mateo, J Puig, J Moltó, N Pérez-Álvarez, B Clotet, E Negredo
A Phase IIIb pilot study substituting darunavir/ritonavir (DRV/r) and etravirine (ETR) for enfuvirtide (ENF) and current PI in a suppressive regimen
P Ruane, B Alas, R Ryan, S Fox, A Perniciaro, J Witek
Efficacy and tolerability of long-term nevirapine plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
CA Carocci, MC Martinelli, MV Mastronardi, CP Corsi, LF Leoncini
Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression
H Byakwaga, JM Murray, K Petoumenos, MA Boyd, S Emery, PW Mallon, DA Cooper
Virological treatment outcome under HAART: does sex matter?
AE Haberl, S Usadel, N Hanhoff, S Holm
Patient characteristics and treatment outcomes associated with protease inhibitor (PI) use in the Asia-Pacific region
SN Pujari, S Sungkanuparph, P Srasuebkul, PL Lim, N Kumarasamy, J Chuah, RN Kumar, P Phanuphak
Use of traditional complementary and alternative medicine (TCAM) by HIV patients prior to initiating ART in KwaZulu-Natal, South Africa
K Peltzer, N Friend-du Preez, S Ramlagan, H Fomundam, J Anderson
Long-term efficacy of boosted and unboosted atazanavir-containing regimens: results from the SCOLTA Project
T Quirino, E Ricci, R Giuntini, C Martinelli, F Vichi, E Gianelli, G Madeddu, B Menzaghi, G De Socio, G Orofino, L Palvarini, G Penco, E Rosella, P Marconi, S Carradori, C Grosso, G Pellicanò, P Bonfanti
Use of lopinavir/ritonavir in first-line therapy or second-line therapy: 48-week results from the German prospective STAR cohort
C Koegl, A Trein, W Schmidt, A Baumgarten, H Jaeger, HJ Stellbrink
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence
S Esser, S Staszewski, AE Haberl, F Mulcahy, J Gölz, A Lazzarin, E Teofilo, J Vera, A Körber, B Ranneberg, L Gallo
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
VT Tuyet Nhung, D Colby, H Thu Thuy, L Vinh Thuy, DT Nhat Vinh, L Truong Giang
Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study
A Abdon, J Cosín, J Pasquau, E Deig, ML Álvarez, P Ferrer, E Pedrol
Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting. The TEAL study
KJ Eccleston, A Bambumba, CS Babu, S Ahmed, V Lee
KAPITAL2: a study of treatment satisfaction reported by patients on lopinavir/r anchored regimens and physicians who provide HIV care
JL Casado, L Griffa, E Cabrero, A Burgos, M Norton
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
B Conway, J DeWet, A Tsang, K Logue, C Kovacs, N Ackad, J Vaillancourt, N Longo, D Haine, JS Sampalis
Good experience of enfurvitide in severely ill patients
K Gyllensten, H Granholm, A Blaxhult
Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status?
R Rubio, MA Johnson, BJ Haas, EA Loeschel, C Granier, F Jackson, HC Pearce
Effect of age on response to and tolerability of highly active antiretroviral therapy: a case-control study
D Francisci, G Masini, R Papili, B Belfiori, F Baldelli
Rarity of mixed cryoglobulinemia (MC) in HIV-1 (+) treatment-naïve patients (09/2006–5/07/2008) and long-term follow-up
S Mourtzoukos, T Kordossis, AN Kontos, AV Theofilopoulou, S Molangeli
Efficacy and safety of ritonavir-boosted fosamprenavir (FPV/r) in HIV-infected patients: 48-week results from an observational study
JF Hain, S Eberle, RK Walli
Management of antiretroviral therapy (ART) in Albania
A Harxhi, D Kraja, E Shehu, E Sharra, S Bino, K Rjepaj
Abacavir and cardiovascular risk in HIV-infected patients: does T-lymphocyte hyperactivation exert a pathogenic role?
M Casana, GM Bellistrì, C Tincati, FB Bai, L Comi, EM Merlini, MC Cristina, T Bini, A d'Arminio Monforte, GM Marchetti
Protease inhibitor atazanavir induces leukocyte-endothelial cell interactions in the microvasculature
MM Andrade, C De Pablo-Bernal, JV Esplugues, Á Álvarez
Anti-inflammatory effect of Omacor during combination antiretroviral therapy: a 12-weeks randomised, double-blind, placebo-controlled trial
M Thusgaard, JH Christensen, B Mørn, TS Andersen, R Vige, H Arildsen, EB Schmidt, H Nielsen
Protease inhibitor-induced cardiotoxicity: direct effects on cell viability and intracellular calcium levels
JP Spiers, C Edwards, A Rietz, E Jan, F Mulcahy, M Hennessy, Y Volkov, AM Davies
Cardiovascular risk estimation in Spanish HIV-infected patients: a multicenter cohort study
E Ferrer, C Minguez, A Mariño, P Geijo, F Brun, J Sanz, M Velasco, C Cortés, A Castro, A Ortí, L Force, P Barrufet, C Villalonga, D Podzamczer
Comparative assessment of coronary risk in HIV-infected patient cohort using Framingham index and Spanish validated coronary risk index: REGICOR
M Cervero Jiménez, R Torres Perea, JL Agud Aparicio, JJ Jusdado Ruiz-Capillas, C García Lacalle, M Álamo del Rodríguez, E García Benaya
Impairment of functional integrity of the vasculature is not changed in patients starting abacavir
S Zona, A Lattanzi, N Squillace, G Orlando, C Stentarelli, R Rossi, AC Nuzzo, MG Modena, G Guaraldi
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough QT study
CE Klein, YL Chiu, BA Da Silva, PA Noertersheuser, WM Awni, CM Holas, TT Doan, B Bernstein
HIV and antioxidant lipoprotein-associated effect. Is there a correlation?
SA Pereira, J Batuca, U Caixas, T Branco, I Germano, F Lampreia, J Delgado-Alves, EC Monteiro
Carotid intima media thickness with no cardiovascular disease in HIV-infected patients correlates with a hyperactivated/pro-apoptotic T-cell phenotype
C Tincati, GM Bellistrì, M Casana, EM Merlini, L Comi, M Olivetti, F Bai, B Teresa, A Gori, A d'Arminio Monforte, GM Marchetti
Impact of fasting bloods on hypertriglyceridemia
NA Billing, GJ Moyle, M Nelson
Do genetic polymorphisms associated with inflammation/lipodystrophy or endothelial damage predict carotid alterations in HIV+ subjects under cART?
K de Gaetano Donati, M Rossi, N Iannotti, M Calbi, A Marzocchetti, A Pedicelli, A Di Castelnuovo, M Fantoni, L Iacoviello, R Cauda, A De Luca
Contribution of antiretroviral therapy, cardiovascular risk factors and constituents of metabolic syndrome to insulin resistance(IR) in HIV
M Cervero Jiménez, R Torres Perea, JL Agud Aparicio, JJ Jusdado Ruiz-Capillas, C García Lacalle, M del Álamo Rodríguez, E García Benaya
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on PR interval: results from a thorough QT study
BA Da Silva, J Li, YL Lin, PA Noertersheuser, WM Awni, CE Klein, TT Doan, B Bernstein
Prevalence of cardiovascular risk factors (CRF) and metabolic syndrome (MS) in a cohort of HIV-infected patients in southern Spain. PREGO study
M Gallego, F Oñate, A del Arco, J Roldan, M Grana, R Palacios, J Santos
Experience of myocardial infarction in a Glasgow HIV cohort
S English, A Winter, R Nandwani, A MacConnachie, A Seaton, R Fox
Sticky platelet syndrome (SPS) in patients with AIDS: a cross-sectional study
H Castro Lopez, L Nieto Cisneros, S Trevino Perez, J Casillas Rodriguez, A Majluf Cruz
Effects of highly active antiretroviral therapy (HAART) on platelet activating factor (PAF) metabolism in HIV-infected patients: in vivo results
AB Tsoupras, M Chini, N Tsogas, N Mangafas, G Stamatakis, S Antonopoulou, CA Demopoulos, MC Lazanas
Peri-renal fat diameter is related to intima media thickness and renal arterial resistance index in HIV-1 infected patients
PF Grima, R Chiavaroli, P Grima
An audit of cardiovascular disease risk management in HIV-infected patients attending a northern English hospital
GL Buxton, DR Chadwick
Effect of antiretroviral therapy on homocysteine plasma concentrations in patients with AIDS
H Castro Lopez, E Coria Ramirez, L Nieto Cisneros, S Trevino Perez, J Casillas Rodriguez, A Majluf Cruz
Traditional risk factors do not predict osteoporosis in HIV patients
NS Chew, S McConkey, J Lambert, G Sheehan, WG Powderly
Metabolic evaluation of Study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1 infected subjects
BA Da Silva, DE Cohen, TM Marsh, LM Fredrick, SE Gibbs, JM Hairrell, B Bernstein, D Grant, C Naylor
Metabolic syndrome among patients initiating HAART and outcome in Southern India
S Saghayam, N Kumarasamy, M Sundaram, S Solomon, G Shivaji, K Mayer, C Wanke
Factors related to low HDL-cholesterol in HIV-infected patients
S Puerta, R Palacios, F Orihuela, J De la Torre, S Fernandez, M Grana, J Rodan, J Santos
HIV infection significantly reduces lipoprotein lipase which remains low after 6 months of antiretroviral therapy
M Boothby, AM Umpleby, F Shojaee-Moradie, JW Tomlinson, LL Gathercole, K McGee, S Das, M Shahmanesh
Long-term satisfaction and benefits on quality of life in HIV-infected people after reparatory treatment with Aquamid®for facial Lipoatrophy
JA Muñoz-Moreno, J Puig, CR Fumaz, E Negredo, MJ Ferrer, N Pérez-Álvarez, V González-Mestre, B Clotet
Virologic failure and metabolic syndrome in patients with HIV infection
N Squillace, S Zona, G Orlando, C Stentarelli, B Beghetto, G Nardini, G Guaraldi
Vitamin D deficiency in the in-patient HIV population: cause or affect?
B Ancock, M Bower, BG Gazzard, M Nelson
Body physical changes in HIV patients under antiretroviral treatment in Spain
L Griffa, E Cabrero, A Burgos
Biochemical markers of bone turnover and calcium dietary intake evaluation in HIV-infected patients
G Camanni, G Toraldo, D Rosignoli, R Pippi, E Schiaroli, G Angeletti, F Baldelli, D Francisci
Assessment for sonographic grading scales of the body fat changes related to the lipoatrophic findings of HIV patients in treatment with HAART
R Gulizia, C Gervasoni, M Ortu, M Galli, C Filice
Efavirenz induces alterations in lipid metabolism through AMPK activation
A Blas-García, D Ballesteros, D Monleón, JM Morales, M Rocha, VM Víctor, N Apostolova, JV Esplugues
Lipid changes in patients receiving nevirapine (NVP) in combination with tenofovir/emtricitabine: results from the CCIAT trial
C Davis, R Talwani, B Gilliam, A Amoroso, C Boyce, P Piliero, C Conner, R Redfield
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
A Wendig, C Stephan, P Khaykin, M Bickel, T Lennemann, G Knecht, T Lutz, N von Hentig, S Staszewski
PI and OPG/RANKL levels in human osteoblast cells
M Borderi, D Gibellini, L Tampellini, C Biagetti, F Vescini, MC Re, F Chiodo
A 24-month follow-up of the metabolic profile of Greek HIV (+) population on lopinavir/ritonavir-based regimen: the ACA GREC trial
SM Metallidis, ML Lazanas, PG Gargalianos, H Sambatakou, NM Magafas, GX Xilomenos, PP Panagopoulos, MG Giannaris, GB Bakoyiannis, KX Xynos, HG Gogos, HB Bassaris, HG Giamarellou, PN Nikolaidis, SK Kourkoudi, KL Loyo
Statistical agreement between ATPIII, IDF, EGIR, AACE metabolic syndrome classifications in HIV-infected patients and association with lipodystrophy
G Guaraldi, S Zona, R D'Amico, N Squillace, G Orlando, C Stentarelli, R Esposito
Hypertension is the most common component of the metabolic syndrome in a cohort of NRTI-based HAART treated patients – a preliminary report
SO Iwuala
Lipid elevations in the ARTEMIS and TITAN trials: effects of demographics, HIV disease stage, treatment arm and lipid-lowering drugs
M Nelson, AM Hill
Kidney tubular abnormalities in HIV patients treated with tenofovir with normal glomerular function – results of a prospective study on 284 patients
P Labarga, P Barreiro, L Martin-Carbonero, S Rodríguez-Nóvoa, C Solera, J Medrano, P Rivas, M Albalate, F Blanco, V Moreno, E Vispo, E Valencia, J González-Lahoz, V Soriano
A cross-sectional comparison of renal function in patients on stable abacavir (ABC) or tenofovir (TDF) containing therapy
LJ Waters, P Randell, AGA Jackson, J Taylor, S Mandalia, BG Gazzard, GJ Moyle
Subclinical kidney disease in HIV-infected patients
ML Sorlí, M Velat, AM Guelar, M Montero, J Villar, G Vallecillo, A Gonzalez, H Knobel
A central body fat distribution is related to increased renal arterial resistance index and renal function impairment in HIV-1 infected patients
PF Grima, P Grima, R Chiavaroli
Introduction of a system to screen for chronic kidney disease and monitor for nephrotoxicity of antiretrovirals at an outpatient HIV clinic
S Kelly, C Bergin, V Treacy, L Sahm, E de Barra
Evaluation of kidney toxicity in HIV patients with tenofovir-based regimen: the role of boosted protease inhibitor in real clinical setting
F Ortu, P Piano, P Serra, R Meleddu, N Corso, PE Manconi
Risk factors for end-stage liver disease among HIV and hepatitis C virus co-infected patients in the Spanish VACH Cohort
R Teira, P Geijo, J Cosín, A Muñoz-Sanz, P Viciana, I Suarez-Lozano, J López-Aldeguer, E Pedrol, F Vidal, T Sanchez, F Lozano, A Terron, A Vergara, MJ Galindo, P Domingo, E Ribera, B Roca, ML Garcia-Alcalde, M Garrido, P Muñoz-Sanchez
Screening for liver fibrosis in HIV-mono-infected patients with increased ALT comparing FibroScan with FIB-4
S Mauss, J Henke, F Berger, P Hegener, G Schmutz
Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
J Absalon, G Thal, A Thiry, R Yang, MD Mancini, D McGrath
Risk factors for advanced liver fibrosis in HIV-infected individuals: role of the metabolic syndrome
F Blanco, P Barreiro, P Ryan, E Vispo, L Martin-Carbonero, P Tuma, P Labarga, J González-Lahoz, V Soriano
Unexplained severe portal hypertension in HIV-infected patients: a new clinical entity?
I Maida, E Vispo, G Sotgiu, P Barreiro, L Martin-Carbonero, MJ Ríos, V Soriano
Statistical agreement between ultrasound (US) and computerized tomography (CT) for non-alcoholic liver disease (NAFLD) diagnosis
S Zona, S Ballestri, A Lonardo, R D'Amico, N Squillace, G Orlando, C Stentarelli, P Loria, G Guaraldi
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
C Stentarelli, S Zona, V Rochira, G Caffagni, L Zirilli, S Ballestri, A Lonardo, R D'Amico, N Squillace, G Orlando, P Loria, G Guaraldi
Hepatic safety of tipranavir/ritonavir (TPV/r)-based antiretroviral therapy: effect of hepatitis virus co-infection and baseline liver fibrosis
J Macias, F Orihuela, A Rivero, P Viciana, M Márquez, J Portilla, MJ Ríos, L Muñoz, J Pasquau, M Castaño, L Abdel-Kader, JA Pineda
Mitochondrial effects of 3 years of CD4-guided HIV treatment interruption
G Garrabou, E Negredo, C Morén, J Romeu, B Rodríguez-Santiago, M Nicolàs, Ò Miró, F Cardellach, J Puig, N Pérez-Álvarez, R López-Blánquez, L Ruiz, R Bellido, C Miranda, B Clotet
Highly active antiretroviral treatment (HAART) interruption leads to an increase in mitochondrial DNA content in HIV-infected children
C Morén, G Garrabou, N Rovira, A Noguera, M Nicolàs, F Cardellach, Ò Miró, C Fortuny
Mitochondrial impairment in HIV-infected children
C Morén, G Garrabou, E Molina, A Noguera, M Nicolàs, F Cardellach, C Fortuny, Ò Miró
Quantitative and qualitative mtDNA-lesions with mitochondrial dysfunction in multiple organs after HAART-associated fatal lactacidosis
J Thoden, D Lebrecht, N Venhoff, JH Neumann, K Müller, UA Walker
Mitochondrial toxicity of antiretrovirals in non-HIV-infected patients
G Garrabou, E Pedrol, E Deig, C Morén, M Nicolàs, P García, I Vidal, F Cardellach, Ò Miró
Uridine supplementation with Mitocnol attenuates mitochondrial cardiomyopathy induced by zidovudine and zalcitabine
K Balcarek, D Lebrecht, C Deveaud, B Beauvoit, J Bonnet, J Kirschner, N Venhoff, UA Walker
Uridine supplementation with Mitocnol antagonizes antiretroviral nucleoside analogue-induced mitochondrial peripheral and cerebral neuropathy in vivo
D Lebrecht, C Deveaud, B Beauvoit, J Bonnet, J Kirschner, K Mueller, N Venhoff, UA Walker
Sensory neuropathy not associated with interruption of ARV therapy in taking stavudine-lamivudine-nevirapine combination HAART in Abuja, Nigeria
O Salami, N Ghaji, C Awunor
Frequency of bone abnormalities and associated factors in a Spanish cohort of HIV-infected patients
A Bonjoch, C Estany, J Puig, P Echeverría, C Caum, B Clotet, E Negredo
A cross-sectional comparison of serum bone markers in patients on stable abacavir (ABC) or tenofovir (TDF) containing therapy
LJ Waters, P Randell, AGA Jackson, J Taylor, S Mandalia, BG Gazzard, GJ Moyle
Osteonecrosis in HIV-infected patients treated with HAART: a case control study of predictors
E Mazzotta, A Agostinone, F Sozio, A Pieri, E Polilli, R Zicolella, F Di Masi, L Alterio, G Parruti, L Di Matteo
Correlates of spinal deforming index (SDI) in HIV-positive patients naive and on treatment
M Casana, T Bini, P Cicconi, G Cuko, A Magenta, L Tagliabue, L Comi, L Pietrogrande, A d'Arminio Monforte
Incidence of infections in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) plus optimized background therapy (OBT)
A Ayoub, J Goodrich, R Tressler, E Van Der Ryst, N Rajicic, K Tomaszewski, HB Mayer
CNA110329: a prospective epidemiological study to determine the prevalence of HLA-B*5701 in HIV-1 infected individuals in five European countries
JM Prins, A Rauch, C Bergin, M Ristola, T Branco, HC Pearce
Gender differences in depression evolution in a cohort of patients attending a metabolic clinic for lipodystrophy management
G Orlando, N Squillace, I Mazeu, B Beghetto, G Nardini, G Guaraldi
Safety analysis of darunavir/r (DRV/r): combined data from randomised Phase II and Phase III studies
G Fätkenheuer, B Clotet, G Pialoux, K Ruxrungtham, C Cohen, J Flamm, T Vangeneugden, E Lefebvre, S Spinosa-Guzman
Study of HIV-positive patients with asymptomatic retroperitoneal lymphadenopathy on antiretroviral therapy for the development of IRIS
AK Tripathi, N Gupta, M Khanna
Quality of life of HIV-infected individuals in a community-based antiretroviral programme
J Pitt, L Myer, R Wood
Health-related quality of life in HIV-infected patients in a private practice in Germany
S Mauss, J Henke, F Berger, P Hegener, G Schmutz
Clinical concentrations of efavirenz (EFV) reduce cellular proliferation and viability in several human cell lines
N Apostolova, A Blas-García, D Ballesteros, Y González, A Morán, LJ Gómez-Sucerquia, JV Esplugues
HIV patients' gastrointestinal tolerability and treatment satisfaction after switching from lopinavir/ritonavir (LPV/r) SGC to co-formulated LPV/r tablets
J Borras-Blasco, JD Rosique-Robles, A Belda, FJ Abad, MDE Castera
Neurotoxic effect of antiretroviral agents on CNS
IW Husstedt, D Reichelt, U Oelker-Grueneberg, S Evers
Evaluation of adherence and toxicities to HAART in a cohort of HIV+ immigrant patients in south-eastern Spain during the period 1998–2007
FJ Vera-Méndez, J Trujillo-Santos, A Cano-Sánchez, JA García-Henarejos, J García-García, OJ Martínez-Madrid, R Vilaplana-García, C Pérez-Pagán, N Cobos-Trigueros, M Alcalde-Encinas, V Herrero-Segastume
Risk factors and clinical and therapeutic issues of pancreatic abnormalities during HIV infection
R Manfredi, L Calza
Relationship between different types of non-adherence behaviour and virological response in unselected HIV-positive cohort
A Ammassari, MP Trotta, P Marconi, M Zaccarelli, P Sette, ML Giancola, P Pierro, S Mosti, RA Acinapura, A Antinori
Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study)
F Maggiolo, M Airoldi, MP Trotta, P Sette, L Bisi, C Mussini, F Bai, T Bini, G Orofino, A Gori
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
R Murri, A Cingolani, A De Luca, S Di Giambenedetto, G Marasca, A Muscatello, V Mazzocato, L Bracciale, E Tamburrini
Factors correlated to non-adherence to antiretroviral therapy among immigrants from poor resource countries, attending a reference center in Rome
P Pierro, P Lorenzini, MP Trotta, P Sette, ML Giancola, N Orchi, M Giulianelli, P De Longis, U Visco-Comandini, A Antinori, M Zaccarelli
Adherence with lopinavir/ritonavir (LPV/r) tablet and SoftGel (SGC) capsule based antiretroviral regimens and predictors of early treatment compliance
TJ Podsadecki, RA Rode, C Naylor, DE Cohen, TM Marsh
Dispositional optimism, perceived health competence and adherence in highly antiretroviral-experienced patients
CR Fumaz, JA Muñoz-Moreno, MJ Ferrer, N Pérez-Álvarez, J Moltó, B Clotet
Challenges to adherence among HIV-positive patients on antiretroviral therapy in Lagos, Nigeria
AO Adeyemi, OO Olaogun, OA Adesola
Loss to follow-up in HIV immigrant patients. Is it a relevant problem? Results of the Spanish COMESEM cohort
M Cervero, R Torres, JL Agud Aparicio, C Barros, G Gaspar, E Casas, R Hervás, A Barrios
Depression in HIV patients is associated with low adherence: a cross-sectional study among HIV patients in Denmark
LO Rodkjaer, T Laursen, N Balle, M Sodemann
Adherence to antiretroviral therapy among children receiving therapy in a resource-poor setting
JE Bisimba, JP Naubutu, E Swai
Adherence, coping strategies and depression in highly antiretroviral-experienced patients
CR Fumaz, JA Muñoz-Moreno, MJ Ferrer, N Pérez-Álvarez, J Moltó, B Clotet
Adherence to antiretroviral therapies in people with HIV infection: a qualitative approach from a narrative-based medicine study
A Tomasini, R Murri, G Guaraldi, N Squillace, G Orlando, S Zona, I Mazeu, MS Aloisi, M Bossola
Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN trial
V Calvez, AM Hill, AG Marcelin
Using the latest resistance score to predict etravirine (ETV) resistance in naïve and NNRTI-failing patients
M Zaccarelli, P Lorenzini, CSF Ceccherini-Silberstein, V Tozzi, F Forbici, MP Trotta, R D'Arrigo, P Marconi, P Narciso, CF Perno, A Antinori
Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: the CASTLE study 48-week results
M Lataillade, R Yang, MD Mancini, D McGrath
Etravirine protects the activity of darunavir in the DUET trials
M Peeters, J Vingerhoets, L Tambuyzer, H Azijn, AM Hill, S De Meyer, G Picchio
HIV lamivudine resistance mutations in HBV co-infected Romanian patients
L Manolescu, P Marinescu, C Sultana, A Temereanca, C Vagu, C Grancea, S Ruta
Are non-B subtypes less susceptible to antiretroviral drugs? A bioinformatical approach to prediction of non-B subtype susceptibility
J Kjær, L Høj, A Cozzi-Lepri, Z Fox, JD Lundgren
Continuous decline in prevalence of drug resistance mutations among naïve and cART experienced HIV-positive patients in Poland over time
GP Stanczak, KJ Przybylska-Stengiel, E Firlag-Burkacka, A Wiercinska-Drapalo, A Horban, JJ Stanczak
Impact of the HIV-1 protease N88S substitution on protease inhibitor susceptibility and clinical response
J Uy, M Lataillade, A Thiry, D McGrath, D Seekins, G Hanna
Correlation between patterns of HIV-1 drug resistance and drug administration in antiretroviral experienced patients in Greece during 1999–2006
D Paraskevis, G Magiorkinis, E Magiorkinis, V Sypsa, PG Gargalianos, MC Lazanas, V Paparizos, A Karafoulidou, T Kordossis, A Antoniadou, H Sambatakou, GL Daikos, A Hatzakis
Reduced susceptibility to lamivudine and emtricitabine associated with the novel K66N mutation in HIV-1 reverse transcriptase
Y Verlinden, G Muyldermans, M Van Houtte, K Van Der Borght, L Rimsky, T Pattery
Incidence of the resistance mutation K65R on reverse transcriptase in different HIV-1 subtypes
D Turner, S Pollack, E Kachman, E Kedem, E Shahar, M Burk, N Matos, G Hassoun, G Grisaru, B Avidor
Activity of etravirine on different HIV-1 subtypes: week 48 data of the pooled DUET trials and in vitro susceptibility in treatment-naïve patients
J Vingerhoets, H Azijn, L Tambuyzer, I Dierynck, S De Meyer, L Rimsky, M Peeters, G De Smedt, MP de Béthune, G Picchio
Genotypic susceptibility to tipranavir of HIV-1 isolates in treatment-experienced patients
P Piliero, L Bhatti, E Coakley, J Scherer, M McDonough, J Baxter
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples
JR Santos, JM Llibre, N Pérez-Álvarez, P Domingo, C Miralles, J Schapiro, B Clotet
Genotypic susceptibility to tipranavir (TPV) and darunavir (DRV) in a cohort of treatment-experienced patients (TEP)
J Baxter, L Bhatti, J Scherer, M McDonough, P Piliero
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
SN Pujari, AN Dravid, N Gupte, A Makne, S Gaikwad, P Mukhopadhaya, B Aich, V Bele
Is HAART based on newest active antiretroviral drugs influenced by GSS?
MO Ortu, PV Vitiello, FA Adorni, RR Rossotti, PDV Di Vincenzo, OV Viganò, M Galli, SR Rusconi
HIV treatment decision making: high rate of revised treatment choices based upon different genotypic interpretation systems
E Wolf, E Gersbacher, M Vogel, A Eberhard, J Goelz, Y Yazdanpanah, J Rockstroh, G Fätkenheuer, S Mauss, C Mayr, H Knechten, I Van Walle, E Jaegel-Guedes, H Jaeger
HIV-1 pol gene diversity and antiretroviral drug resistance mutations in Itanhaém city, Brazil
RB Rodrigues-Matias, KCP Guatelli, RF Ambar, NB Duarte, LH Gagliani, S Komninakis, V Candido, MM Caseiro, DJ Sa-Filho
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
L Trinh, D Han, W Huang, T Wrin, J Larson, L Kiss, E Coakley, CJ Petropoulos, N Parkin, JM Whitcomb, JD Reeves
Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in South Africa infected with Clade C virus
S Eng, I Sanne, S Badal-Faesen, R Wood, N Rajicic, R Tressler
Therapeutic drug monitoring of new formulation Kaletra in pregnancy
V Jackson, LJ Else, SH Khoo, SE Gibbons, M Brennan, EO Connor, N Boyle, C Fleming, S Coulter-Smith, J Lambert
Elite controllers or misquantification of virus load by Cobas TaqMan?
N Taylor, M Jauer, K Bijuklic, A Egle, R Greil, W Patsch, M Obermeier, J Eberle
Determination of HIV-1 co-receptor usage in German patients – comparison of genotypic methods with the TROFILE® phenotypic assay
MJ Obermeier, T Berg, N Sichtig, P Braun, MP Däumer, H Walter, C Noah, E Wolf, H Müller, M Stürmer, A Thielen, R Kaiser
Influence of gender in predicting CCR5 coreceptor usage
S Nozza, A Soria, F Visco, C Vinci, F Cossarini, V Spagnuolo, B Barda, L Della Torre, A Castagna, A Lazzarin, L Galli, G Tambussi
Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification
X Couto-Parada, A Lee, I Ushiro-Lumb, J Anderson, G Baily, S Limb, H Noble, C Orkin, I Reeves, A Oliver, D Clark
Estimating renal impairment and evaluating antiretroviral dose adjustments among HIV-positive patients: a comparison of three hospitals
K Mackie, R Weston, S Sonecha, A Murungi, A Duncan
Reproducibility of a high-throughput HIV-1 genotypic resistance assay over time (2001–2007)
A Deloof, G Muyldermans, T Pattery, P Mc Kenna, A Van Cauwenberge, H De Wolf, M Van Houtte
Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients
R Maserati, M Clerici, M Lauriola, M Pacei, M De Gennaro, E Chiesa, M Coen, R Terzi, DH Bray, S Lo Caputo
Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar
H Teppler, J Rockstroh, R Isaacs, H Wan, C Hervey, M Miller, BY Nguyen
Effect of hemolysis on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a 2-year analysis
T Pattery, I Bovee, E Rousseau, N Hartmans, P Mc Kenna
Analysis of viral load, CD4+ and CD8+ T-cell from HIV-1 infected patients enrolled in the AIDS programs from the city of Santos, Brazil
AC Zetehaku, AFP Lins-Filho, JT Rabelato, JC Tobara, NC Nahon, NT Santos, RBR Matias, RG Comparini, RF Ambar, LH Gagliani, S Komninakis, RS Diaz, AAC Golegã, MM Caseiro, DJ Sa-Filho
Measurement of 3-methylhistidine in spot urine from HIV-infected persons: an alternative screening method for muscle protein degradation to serum CK
AC Venhoff, E Bissé, T Epting, J Thoden, UA Walker, N Venhoff
Analysis of HIV variants in blood and semen in serodiscordants by heteroduplex mobility assay
SK Jadhav, SM Velhal, A Deshpande, AH Bandivdekar
Activation of HIV-specific CD8+ T lymphocytes by histamine depends also on the total NK cells
D Sedláèek, J Hanzlíková, M Liška, J Gorèíková, S Amiramini, P Panzner
D-dimer and anti-coagulation activity markers in children and adolescents with HIV infection
G Pontrelli, H Tchidjou, R Citton, N Mora, P Palma, A Martino, P Rossi, S Bernardi
Tenofovir toxicity in children: two clinical cases
AS Bengleil, M Kambraki, O Al Fituri, I El Ammari, A Idris Elteer, AM Martino
Impact on bone mineral density of tenofovir-containing HAART in HIV-1 infected children and adolescents: a report from 5 years of clinical experience
R Rosso, A Di Biagio, A Parodi, C Torrisi, F Ginocchio, F De Terlizzi, M Vignolo, C Viscoli
Progression to AIDS in HIV vertically infected children diagnosed and ARV treated from first year of life
S Dobosz, M Marczyñska, A Oldakowska, M Szczepañska-Putz
cART in vertically HIV-infected children treated since infancy
M Marczyñska, A Oldakowska, S Dobosz, M Szczepasñka-Putz, J Popielska
Prevention of mother-to-child transmission of HIV in the HAART era: patterns in use of neonatal prophylaxis
K England
Regular audit can lead to changes in practice and better outcomes for pregnant women with HIV
V Patton, R Fox, R Nandwani, A Seaton, A MacConnachie, M Hepburn, E Ellis, H Mactier, A Winter
Abstract withdrawn
Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancy
JM Peña, MI González, JF Pascual-Pareja, J López-Aldeguer, JA Iribarren, M Leyes, P Miralles, J Sanz, A Ocampo, JL Gómez-Sirvent, JT Ramos
Efficacy and safety of Truvada®in HIV-1 pregnant women: report of 23 cases
N Ciraru-Vigneron, MC Mazeron, V Lefevre, N Chernai, H Trout, JF Bergman, E Barranger
Outcome of pregnancies in HIV-positive women followed up at the Institute of Tropical Medicine (ITM) in Antwerp, Belgium, between 1997 and 2007
I Kint, J Pelgrom, P Maes, K Wouters, S Caluwaerts, A Buvé
Particular aspects of mother-to-child transmission of HIV infection: single center's 7-year experience in Romania
C Oprea, E Ungureanu, R Radoi, S Tetradov, G Tardei, D Duiculescu
Managing HIV in pregnancy in Glasgow
V Patton, R Fox, R Nandwani, A Seaton, A MacConnachie, M Hepburn, E Ellis, H Mactier, A Winter
Materno-fetal transmission of HIV infection in Constanta county in the last 8 years
SC Cambrea, MM Ilie, C Marcas, S Rugina, CN Rugina
HIV maternal-fetal transmission in a low resources setting in the outskirts of Buenos Aires, Argentina
M Hojman, F Murano, G Manonelles, M Maldonado, N Ahmed, M Sanchez Vera, M Prieto
Prevalence and risk factors associated with loss to follow-up in a cohort of HIV-infected patients treated with highly active antiretroviral treatment
S Morreel, T Schepens, E Florence, I Kint, O Koole, R Colebunders
Clinical mentoring: a sustainable strategy for scaling up HIV/AIDS clinical expertise in developing countries
S Aggett, K Shantz, R Mair, M Charles
Patient satisfaction survey for the home delivery of medication scheme
B Smith, S Sonecha, A Murungi, M Nelson
Ten years of non-occupational HIV post-exposure prophylaxis: what have we learned?
F Tissot, V Fardel, M Cavassini
Occupational HIV exposure among Thai healthcare workers: an analysis of 558 exposures during 1998–2007
P Wangpatharawanit, W Padiwongpaisarn, N Phanuphak, P Phanuphak
Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR gene
M Siccardi, A D'Avolio, L Baietto, A Calcagno, SE Gibbons, M Sciandra, S Bonora, SH Khoo, DJ Back, G Di Perri, A Owen
Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction
M Giola, M Cusato, P Villani, C Basilico, D Bernasconi De Luca, L Lazzaroni, L Rizzi, PA Grossi
Predictors of severe hyperbiliruniaemia in HIV-infected patients treated with atazanavir (ATV)
M Casana, A Barassi, P Cicconi, T Bini, L Comi, O Turri, F Pateri, ML Biondi, GL Melza d'Eril, A d'Arminio Monforte
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
J Svard, JP Spiers, F Mulcahy, M Hennessy
Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs
A Chaikan, N Chierakul, N Saguenwong, C Chuchuttaworn, A Owen, L Dickinson, SH Khoo, DJ Back, GR Davies
Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrations
V Shallcross, WS Kwan, R Hartkoorn, T Mahungu, SH Khoo, DJ Back, A Owen
The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)
HM Crauwels, RPG van Heeswijk, D Kestens, M Stevens, A Buelens, K Boven, RMW Hoetelmans
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
RD Bruce, FL Altice, DE Moody, S Lin, WB Fang, JP Sabo, JM Wruck, C Conner, P Piliero, L Andrews, GH Friedland
Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study
L Dickinson, M Boffito, LJ Else, GJ Moyle, SH Khoo, A Pozniak, L Aarons
Quantitation of raltegravir in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of LC-MS/MS
R ter Heine, H Rosing, ECM van Gorp, JW Mulder, JH Beijnen, ADR Huitema
Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia
M Fabbiani, S Di Giambenedetto, E Ragazzoni, M Colafigli, M Prosperi, R Cauda, P Navarra, A De Luca
Impact of age on pharmacokinetics of boosted atazanavir 300/100 in Thai HIV-infected patients
A Avihingsanon, J van der Lugt, S Kerr, M Gorowara, S Chanmano, DA Cooper, P Phanuphak, D Burger, K Ruxrungtham
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation
J Ng, CE Klein, P Diderichsen, BA Da Silva, B Bernstein, WM Awni, YL Chui
Therapeutic drug monitoring of atazanavir in pregnancy
J Lambert, LJ Else, V Jackson, SE Gibbons, M Brennan, J Kieran, J Breiden, S Coulter-Smith, SH Khoo
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects
J Ng, CE Klein, YL Chui, WM Awni, JB Morris, TJ Podsadecki, Y Cui, B Bernstein, D Kim
Ezetimibe as lipid-lowering therapy for patients receiving HAART
AK Asghar, M Bower, P Holmes, BG Gazzard, H Isenman, M Nelson
Once-daily darunavir (DRV) used in routine clinical care produces trough DRV drug concentrations in excess of 30× the protein-corrected (PC) EC50for wild-type HIV
CM Robertson, AN Jayasuriya, CJ Smith, S Taylor, NE Dufty, A Berry, C Stradling
An open-label multicentre pilot study evaluating the pharmacokinetics (PK) of co-administered lopinavir (LPV) and nevirapine (NVP) in HIV+ adults
LJ Else, TW Mahungu, Z Cuthbertson, CJ Smith, D Podlekareva, P Hay, UB Dragsted, SH Khoo, MA Johnson, DJ Back, M Youle
Is prognosis after first AIDS-defining pathology incidence becoming better in recent years of HAART era?
G Gaspar, JA Melero, E Contés, J Sanz, JJ Jusdado, V Castilla, A Barrios, MT de Guzmán
Peripheral blood CD4+ T-lymphocyte count influences cerebrospinal fluid cellular response in patients with HIV-related cryptococcal meningitis
DM Cecchini, AM Cañizal, H Rojas, A Arechavala, R Negroni, MB Bouzas, J Benetucci
Early predictors of outcome and management of PCP in Glasgow: 11 years experience in the post-antiretroviral era
CL Mackintosh, A MacConnachie, R Nandwani, A Seaton, A Winter, R Fox
Clinical and immuno-virologic outcome in a cohort of immigrant and native subjects with HIV infection in south-eastern Spain during the period 1998–2007
FJ Vera-Méndez, J Trujillo-Santos, A Cano-Sánchez, JA García-Henarejos, N Cobos-Trigueros, J García-García, OJ Martínez-Madrid, R Vilaplana-García, C Pérez-Pagán, M Alcalde-Encinas, V Herrero-Segastume
Impact of highly active antiretroviral therapy on cytomegalovirus viraemia, in the absence of specific anti-cytomegalovirus therapy
R Mihailescu, S Paraschiv, V Arama, A Streinu-Cercel, D Otelea, OE Benea, M Iosipenco, M Mardarescu, M Luminos, D Munteanu, M Radulescu, C Chiotan, A Hristea, R Ungurianu
23% of newly diagnosed HIV cases in 2007 at Karolinska University Hospital had opportunistic infections
K Egnell, V Svedhem
Impact of CMV infection on horizontally transmitted HIV-1 disease progression
A Cupsa, F Dumitrescu, L Giubelan, T Kalath, A Romanescu, I Niculescu, N Anghel
Retrospective evaluation of cases of CNS toxoplasmosis in patients with AIDS hospitalized in the Department of Hospital for Infectious Diseases, Warsaw
MA Miarka, J Gizinska, D Latarska-Smuga, RB Podlasin
Factors associated with positive tuberculin skin test results in HIV-1 infected Thai patients
NT Teeratakulpisarn, SP Phositlimakul, PS Suwanmala, CW Wongsuthipol, TP Pankam, NP Phanuphak, CB Burapat, TT Tasaneeyapan, WK Kittikraisak, KDM McCarthy, KPC Cain, JKV Varma, P Phanuphak
High rates of viral suppression in HIV/TB patients treated with NNRTI-based antiretroviral therapy
LJ Campbell, A Samarawickrama, AC Bailey, E Hamlyn, J Ashby, A Winston, FA Post
Clinical epidemiology of HIV and tuberculosis co-infection in Galati, Romania
M Arbune, C Scorpan, OE Benea
Characteristics distinguishing disseminated Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacterial (NTM) infection in HIV patients
AC Bailey, A Samarawickrama, F Ibrahim, RD Barker, FA Post
Incidence of immune reconstitution inflammatory syndrome among HIV patients infected with tuberculosis in a Dublin cohort
EG Muldoon, M Mokoka, P Kok, C McNally
Cross-sectional study to determine prevalence of significant liver fibrosis (F2–F4) in HIV/HCV co-infected patients: GRAFIHCO study
C Tural, E Ortega, JA Pineda, J Gonzalez-García, L Griffa, E Cabrero, A Burgos
A 4-year follow-up of a cohort of HIV-positive cirrhotic patients
P Tuma, E Vispo, J Medrano, P Barreiro, L Martin-Carbonero, P Labarga, V Soriano
Rapid virological response is the best predictor for achieving SVR under peg-IFN/ribavirin hepatitis C therapy in HIV/HCV co-infected patients
M Janke, G Luechters, M Vogel, E Voigt, JC Wasmuth, C Schwarze-Zander, J Emmelkamp, G Fätkenheuer, J Rockstroh
Switching from zidovudine/lamivudine (ZDV/LMV) to tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/LMV) in HIV/HCV co-infection (COTKI study)
P Nasta, F Gatti, A Matti, G Carosi
HCV relapse after peg-interferon (IFN) plus ribavirin (RBV) therapy: is 12-week follow-up enough to determine sustained HCV clearance?
J Medrano, S Resino, E Vispo, P Tuma, J García-Samaniego, L Martin-Carbonero, P Labarga, I Jimenez, M Romero, P Barreiro, V Soriano
Frequency of hepatic steatosis in HIV and hepatitis C co-infected patients treated by antiretroviral therapy during 1995 to 2008
V Martinez, N Thi Dieu TA, M Guiget, Z Mokhtari, MA Valantin, F Charlotte, P Bertheau, JM Molina, C Katlama, E Caumes
Acute hepatitis C infection in a cohort of HIV-infected patients in Belgium
E Florence, E Bottieau, M Van Den Boer, M Vekemans, S Francque, E Vlieghe, P Soentjens, R Colebunders
Rapid rebound in hepatitis B DNA in previously undetectable hepatitis B/HIV co-infected patients switching from tenofovir to entecavir therapy
M Hull, J Toy, V Montessori, M Harris, G Ritchie, C Sherlock, JSG Montaner
Safety and tolerability of etravirine (ETR; TMC125) in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results
B Clotet, C Katlama, A Lazzarin, K Jansen, TN Kakuda, G De Smedt
Absence of liver steatosis in HIV-infected patients receiving tenofovir-containing regimen
V Borghi, C Mussini, L Manzini, L Bisi, R Esposito
Impact of hyperglycemia and cholesterol levels on the outcome of hepatitis C treatment in HIV/HCV co-infected patients
M Cesari, I Caramma, S Antinori, OV Viganò, M Galli, L Milazzo
Presence of hepatitis B virus in cerebrospinal fluid of HIV-1 co-infected adolescents
D Duiculescu, L Ene, G Tardei, C Ionescu, S Ruta
Continuing evidence to support the role of early kinetic monitoring in predicting sustained viral response for HIV/HCV co-infected patients
J Kieran, A Jackson, DO Shea, G Farrell, J Thornhill, C McNally, F Mulcahy, C Bergin
Substitution of tenofovir for nucleoside analogues in virologically controlled HIV-infected patients co-infected with hepatitis C virus: TEN-SWITCH
J Grebely, L Gallagher, E Knight, K Genoway, M Storms, HK Tossonian, M Hosseina, G Showler, JD Raffa, C Fraser, F Duncan, B Conway
Efficacy of shorter duration HCV treatment in injection drug users (IDUs)
A Barrieshee, B Conway
Hepatitis B virus (HBV) genotype distribution and lamivudine-resistant mutations in HIV/HBV co-infected patients attending a Parisian hospital
N Schnepf, C Lafuente-Lafuente, I Jarrin, G Simoneau, JD Magnier, A Trylesinski, P Sellier, MC Mazeron
Abstract withdrawn
Abstract withdrawn
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
P Nasta, F Gatti, G Cologni, A Matti, M Monia, G Carosi
Treatment outcome of chronic hepatitis C in HIV-infected patients at the Institute of Tropical Medicine, Antwerp, Belgium, from 2000 to 2008
E Bottieau, E Florence, M De Boer, E Vlieghe, R Demeester, M Vekemans, F Moerman, L Lynen, S Francque, P Michielsen
Outcome of chronic hepatitis delta in patients with and without HIV infection in the HAART era
P Tuma, E Vispo, P Barreiro, A Madejon, J Medrano, R Romero, M Bottecchia, J García-Samaniego, V Soriano
HCV genotypes distribution in the Nizhny Novgorod area HIV-positive population
S Minaeva, G Moshkovich, E Tikhonova, O Sandova
Thrombopenia and/or splenomegaly in HIV/HCV co-infected patients with mild liver fibrosis alerts for the risk of portal hepatopathy
E Vispo, I Maida, P Barreiro, V Moreno, V Soriano
Increased ribavirin dose in HIV/HCV co-infected patients leads to increased serum concentration of ribavirin
F Almasi, G Spiridon, V Jullien, JF Merritet, P Sogni, D Salmon
Predictors of immune reconstitution inflammatory syndrome associated with Kaposi sarcoma (IRIS-KS) in a rural area of Mozambique
E Letang, J Almeida, E Ayala, JM Miro, C Carrilho, R Bastos, D Nhassone, J Gascon, C Menendez, PL Alonso, D Naniche
Impact of HIV treatment on clearance of human papillomavirus (HPV) infection in HIV-infected women
D Konopnicki, Y Manigart, R Scheen, M Delforge, P Barlow, S De Wit, N Clumeck
Rituximab and Castleman disease and Kaposi's sarcoma
J Lobo, C Gallo, M R-Junquera, V Carcaba, J A-Megido, S Santos, A G-Franco, I Suarez
The use of enfuvirtide-based HAART regimens in HIV patients undergoing chemotherapy for lymphoma
BA White, R Fox, J Laird, A Seaton, A MacConnachie
Factors associated with anxiety, depression and cognitive impairment in elderly patients receiving HAART
G Liuzzi, S Menichetti, R Libertone, MF Salvatori, P Balestra, R Bellagamba, A Antinori, V Tozzi
Varicella vaccination in HIV-positive individuals – a time to act
E de Barra, C Rock, B Kiely, C McNally, F Lyons, C Bergin
HPV infection in HIV-positive subjects and molecular epidemiology
K Protopas, S Tsiodras, K Chranioti, A Papadopoulos, P Panagopoulos, J Georgoulakis, A Antoniadou, V Sakka, L Galani, D Kavatha, G Poulakou, A Spathis, I Katsarolis, I Karaiskos, J Panagiotidis, P Karakitsos, HG Giamarellou
GBV-C/HIV co-infected patients from AIDS Center Prague have higher CD4 cell counts and probably better quality of life
V Aster, J Konig, H Rozsypal, L Machala, O Urbankova, M Stankova
Hospital admissions and associated diagnosis of HIV patients in the HAART era
A Prisca, C Caldas, S Xerinda, D Ferreira, R Coelho, S Cardoso, S Rocha, A Ferreira, R Marques, A Sarmento
Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy
SL Pett, J Zaunders, M Bailey, DA Cooper, K MacRae, S Emery, A Kelleher
Results of a Phase I study to evaluate the safety, tolerability, pharmacokinetics (with and without ritonavir) and food-effect of VCH-286
L Proulx, N Chauret, P Clermont, J Laterreur, R Thibert
What about primary pulmonary hypertension in HIV infection in the era of combination antiretroviral therapy?
M Mary-Krause, C Lascoux-Combe, A Simon, E Teicher, D Costagliola
Age-related co-morbidities in people living with HIV
G Guaraldi, S Zona, G Orlando, N Squillace, C Stentarelli, G Nardini, B Beghetto, R Esposito, FJ Palella
Do cerebral function test results correlate when measured by a computerised battery test and a memory questionnaire in HIV-1 infected subjects?
LJ Garvey, D Yerrakalva, A Winston
Sexual dysfunction in HIV-infected women: prevalence and related factors
AM Guelar, J Villar, ML Sorlí, M Velat, O Urbina, A Gonzalez, H Knobel
Increased risk for acute HIV infection from non-ulcerative STI's in MSM: aggressive STI eradication programs needed for reduction in HIV incidence
RK Bolan, SD Tilekar, E Clay, A Uniyal, M Chein, PR Kerndt, JD Scott
Distribution of autoantibodies and rheumatological manifestations in HIV-positive patients from the University Clinic of Bonn – a pilot study
EA Becker, JC Wasmuth, E Voigt, C Schwarze-Zander, J Emmelkamp, J Rockstroh
Perceptions of obesity amongst a mixed HIV cohort in London, UK – Slim is no longer Slim
CS Bradbeer, MS Abu Bakar
NRTI backbone pairs for treatment-naïve adults with HIV infection: a UK economic evaluation
AJ Brogan, F Everhard, SE Talbird, E Hutt, E Zimovetz
Cost-effectiveness of switching to second-line therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda
KN Simpson, B Dietz, SX Rahim, R Rajagopalan
96 weeks pharmacoeconomic outcome of lopinavir/r monotherapy as maintenance strategy in HIV+ patients with suppressed viral load. OK04-PharmECO analysis
JR Arribas, F Pulido, I Méndez, P Lázaro, M Norton, E Cabrero, A Burgos
Cost-effectiveness of tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults with HIV infection in the USA
AJ Brogan, F Everhard, SE Talbird, E Hutt
An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UK
E Elbasha, W Dunlop, MA Chaudhary, RN Kumar
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
KN Simpson, R Rajagopalan, B Dietz
Economic modeling of the combined effects of HIV disease, heart disease and lipoatrophy based on ACTG 5142 trial data
KN Simpson, R Rajagopalan, B Dietz, K Garren, S Riddler, R Haubrich
Cost-effectiveness of DRV/r 600/100 mg BID in treatment-experienced, LPV/r-naïve, PI-resistant, HIV-infected adults in the UK, Belgium, Italy and Sweden
K Moeremans, LC Hemmett, J Hjelmgren, G Allegri, E Smets
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
D Nieves, O de la Calle, JA Iribarren, A Rivero, L García-Bujalance, I Pérez-Escolano, M Brosa
A cost-effectiveness analysis of Maraviroc in treatment-experienced HIV patients in Scotland
I Lekander, J Berg, A Christie, C Leen, M Nelson
Cost-minimisation analysis of the use of etravirine or raltegravir in treatment-experienced HIV-1-infected patients
S Martin, E Smets
Non-nucleoside-based antiretroviral regimens are most durable and cost-effective as first treatments in an urban setting from a developing country
E Bissio, GD Lopardo
Cost consequences of HIV-associated lipoatrophy
J Hornberger, R Rajagopalan, A Shewade, M Loutfy